title: Reduced transplant arteriosclerosis in plasminogen-deficient mice.
abstract: Recent gene targeting studies indicate that the plasminogen system is implicated in cell migration and matrix degradation during arterial neointima formation and atherosclerotic aneurysm formation. This study examined whether plasmin proteolysis is involved in accelerated posttransplant arteriosclerosis (graft arterial disease). Donor carotid arteries from wild-type B10.A2R mice were transplanted into either plasminogen wild-type (Plg+/+) or homozygous plasminogen-deficient (Plg-/-) recipient mice with a genetic background of 75% C57BL/6 and 25% 129. Within 15 d after allograft transplantation, leukocytes and macrophages infiltrated the graft intima in Plg+/+ and Plg-/- recipient mice to a similar extent. In Plg+/+ recipients, the elastic laminae in the transplant media exhibited breaks through which macrophages infiltrated before smooth muscle cell proliferation, whereas in Plg-/- recipients, macrophages failed to infiltrate the transplant media which remained structurally more intact. After 45 d of transplantation, a multilayered smooth muscle cell-rich transplant neointima developed in Plg+/+ hosts, in contrast to Plg-/- recipients, in which the transplants contained a smaller intima, predominantly consisting of leukocytes, macrophages, and thrombus. Media necrosis, fragmentation of the elastic laminae, and adventitial remodeling were more pronounced in Plg+/+ than in Plg-/- recipient mice. Expression of the plasminogen activators (PA), urokinase-type PA (u-PA) and tissue-type PA (t-PA), and expression of the matrix metalloproteinases (MMPs), MMP-3, MMP-9, MMP-12, and MMP-13, were significantly increased within 15 d of transplantation when cells actively migrate. These data indicate that plasmin proteolysis plays a major role in allograft arteriosclerosis by mediating elastin degradation, macrophage infiltration, media remodeling, medial smooth muscle cell migration, and formation of a neointima.
authors.affiliation: Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, B-3000 Leuven, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Moons
authors.forename: C
authors.initials: C
authors.lastname: Shi
authors.forename: V
authors.initials: V
authors.lastname: Ploplis
authors.forename: E
authors.initials: E
authors.lastname: Plow
authors.forename: E
authors.initials: E
authors.lastname: Haber
authors.forename: D
authors.initials: D
authors.lastname: Collen
authors.forename: P
authors.initials: P
authors.lastname: Carmeliet
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D002339:Carotid Arteries / Q000201:enzymology / Q000473:pathology* / Q000637:transplantation; D002455:Cell Division; D002465:Cell Movement; D004730:Endothelium, Vascular / Q000276:immunology / Q000473:pathology; D006789:Host vs Graft Reaction; D007150:Immunohistochemistry; D008264:Macrophages / Q000166:cytology; D008297:Male; D008666:Metalloendopeptidases / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D010958:Plasminogen / Q000235:genetics / Q000502:physiology*; D010960:Plasminogen Activators / Q000378:metabolism
chemical_list: D010958:Plasminogen; D010960:Plasminogen Activators; D008666:Metalloendopeptidases